Skip to main content

Abstract

All infants without contraindications should receive the rotavirus vaccine series; consisting of either two oral doses of RV1 (trade name: Rotarix®) or three oral doses of RV5 (trade name: RotaTeq®) beginning at about 2 months of age (no earlier than 6 weeks of age). Each dose should be separated by at least 4 weeks, and given at the same time as other normal childhood vaccinations. Maximum age of the first dose of rotavirus vaccination is 14 weeks and 6 days, and maximum age for any dose is 8 months.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Epidemiology and Prevention of Vaccine-Preventable Diseases, Hamborsky J, Kroger A, Wolfe S, eds. 2015, Centers for Disease Control and Prevention: Washington D.C.

    Google Scholar 

  2. Cortese, M.M. and U.D. Parashar, Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep, 2009. 58(Rr-2): p. 1–25.

    PubMed  Google Scholar 

  3. Aliabadi, N., J.E. Tate, and U.D. Parashar, Potential safety issues and other factors that may affect the introduction and uptake of rotavirus vaccines. Clin Microbiol Infect, 2016. 22 Suppl 5: p. S128–s135.

    Article  CAS  Google Scholar 

  4. Yih, W.K., et al., Intussusception risk after rotavirus vaccination in U.S. infants. N Engl J Med, 2014. 370(6): p. 503–12.

    Article  CAS  Google Scholar 

  5. Parashar, U.D., et al., Value of post-licensure data on benefits and risks of vaccination to inform vaccine policy: The example of rotavirus vaccines. Vaccine, 2015.

    Google Scholar 

  6. Centers for Disease Control and Prevention. Vaccine Information Statements (VIS). August 7, 2015 [cited 2015; Available from: http://www.cdc.gov/vaccines/hcp/vis/current-vis.html.

  7. Bogaert, D., et al., Persistent rotavirus diarrhea post-transplant in a novel JAK3-SCID patient after vaccination. Pediatr Allergy Immunol, 2016. 27(1): p. 93–6.

    Article  Google Scholar 

  8. Bakare, N., et al., Severe combined immunodeficiency (SCID) and rotavirus vaccination: reports to the Vaccine Adverse Events Reporting System (VAERS). Vaccine, 2010. 28(40): p. 6609–12.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Dudley, M.Z. et al. (2018). Rotavirus. In: The Clinician’s Vaccine Safety Resource Guide. Springer, Cham. https://doi.org/10.1007/978-3-319-94694-8_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-94694-8_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-94693-1

  • Online ISBN: 978-3-319-94694-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics